2 results
Approved WMORecruiting
Objective: To demonstrate the efficacy of a novel matrix therapy based technology that creates improved wound healing in a clinical donor site model.
Approved WMORecruiting
The purpose of this Phase II/III study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7204239, a humanized monoclonal antibody that binds to human latent myostatin, in combination with risdiplam (…